DEEP LEARNING DOSE PREDICTION MODELS
MACHINE LEARNING FASTER AND SMARTER TREATMENT PLANNING
Generate treatment plans automatically with deep learning driven dose prediction. RaySearch provides your clinic with a roster of machine learning models that have been validated against common radiotherapy treatment protocols. Details about the treatment protocols can be found in the respective model data sheets.
RSL BREAST LOCOREGIONAL 2LVS*
Validation patient example
MODEL OVERVIEW
Treatment site
Breast (or thoracic wall) and nodes
Modality Photons
Treatment technique
Validated for VMAT
Primary prescription [cGy] 6000
Number of fractions 25
Dose per fraction [cGy] 240
MODEL PROTOCOL
Clinical goals varied based on primary target (either breast or thoracic wall) and the involved lymph nodes. Clinical goal values given in the table below represent the ones used for breast with all lymph nodes involved.
ROI
PTV1
PTV1
PTV1
PTV2
PTV2-PTV1
PTV3
PTV3
PTV4
PTV4
PTV5
PTV5
PTV6
PTV6
Organs at risk
Clinical goals
At least 5989 cGy average dose
At least 5700 cGy dose at 99.1 % volume
At most 6180 cGy dose at 0.5 % volume
At least 4750 cGy dose at 98.4 % volume
At most 5250 cGy dose at 9.6 % volume
At least 4750 cGy dose at 99.2 % volume
At most 5250 cGy dose at 0 % volume
At least 4750 cGy dose at 96.0 % volume
At most 5250 cGy dose at 0.1 % volume
At least 4750 cGy dose at 98.0 % volume
At most 5250 cGy dose at 0.1 % volume
At least 4750 cGy dose at 96.2 % volume
At most 5250 cGy dose at 0.6 % volume
Clinical goals varied based on primary target volume and lymph node involvement
*This functionality is in RayStation v2025 SP1, which is pending FDA 510(k) clearance and is not currently available for sale or clinical use in the United States.
ADVANCING CANCER TREATMENT
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch® markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand®**, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
*Subject to regulatory clearance in some markets.
**RayCommand is not available for use or sale in the USA or Canada.